Open Beta
TREN
MetriLume
TREN

US marketsCANF

SEC-sourced researchBeta

CANF

Can-Fite BioPharma Ltd.

Company comparison ↗

Data passport

CIK
0001536196
Exchange
NYSE
Business activity
— · SIC 2834
Financial inputs
5/6
Filing date
Sep 25, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 743,000.0000 USD; December 2024: 674,000.0000 USD; December 2025: 405,000.0000 USD743K USD0 USD0December 2023December 2024December 2025
CANF · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023743,000.0000Mar 26, 2026
December 2024674,000.0000Mar 26, 2026
December 2025405,000.0000Mar 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025405,000.0000-9,828,000.0000-8,949,000.00009,514,000.0000—Mar 26, 2026
December 2024674,000.0000-7,880,000.0000-7,637,000.00009,120,000.0000—Mar 26, 2026
December 2023743,000.0000-7,634,000.0000-8,440,000.0000——Mar 26, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$405KDecember 2025Mar 26, 202620-F
Previous period revenueRevenues$674KDecember 2024Mar 26, 202620-F
Net incomeNetIncomeLoss-$9.83MDecember 2025Mar 26, 202620-F
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$8.95MDecember 2025Mar 26, 202620-F
Total assetsAssets$9.51MDecember 2025Mar 26, 202620-F
Total liabilities————

New filings

Explore methodology ↗